Key Takeaways & Executive Findings
- •• The proposed blockchain-based system ensures end-to-end traceability and tamper-proof records in the drug supply chain, significantly reducing counterfeit drugs. • Integration of smart contracts automates compliance and verification processes, enhancing operational efficiency and reducing administrative overhead. • The system's decentralized architecture improves data integrity and security, fostering trust among stakeholders. • Feasibility and performance evaluations show the system is convenient and fast, making it practical for real-world deployment.
Abstract
The pharmaceutical supply chain faces significant challenges including counterfeit drugs, lack of transparency, and inefficient management. This paper proposes a blockchain-based drug supply chain security and management system to address these issues. The system leverages a closed-loop blockchain architecture to ensure end-to-end traceability and tamper-proof records. By integrating smart contracts and decentralized storage, the system enhances data integrity, security, and operational efficiency. The implementation demonstrates that the proposed system is feasible, convenient, and fast, improving the overall management of pharmaceutical supply chains and ensuring patient safety.
1. Introduction
The pharmaceutical supply chain is a complex network involving manufacturers, distributors, pharmacies, and patients. Counterfeit drugs and lack of transparency pose serious risks to patient safety and public health. Traditional supply chain management systems often rely on centralized databases that are vulnerable to tampering and single points of failure. Blockchain technology, with its decentralized and immutable ledger, offers a promising solution to enhance security and traceability.
This paper presents a blockchain-based drug supply chain security and management system. The system utilizes a closed-loop blockchain architecture to ensure end-to-end traceability and tamper-proof records. By integrating smart contracts and decentralized storage, the system enhances data integrity, security, and operational efficiency. The implementation demonstrates that the proposed system is feasible, convenient, and fast, improving the overall management of pharmaceutical supply chains and ensuring patient safety.
Loading authentic research manuscript (Pages 1–5)...
Anonymous (2026). Drug Supply Chain Security and Management System Based on Blockchain Technology. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_215
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main problem addressed by this paper?
The paper addresses the issues of counterfeit drugs, lack of transparency, and inefficient management in the pharmaceutical supply chain.
How does blockchain technology improve drug supply chain security?
Blockchain provides a decentralized and immutable ledger, ensuring tamper-proof records and end-to-end traceability, which reduces the risk of counterfeit drugs and enhances data integrity.
What are the key components of the proposed system?
The system includes a closed-loop blockchain architecture, smart contracts for automated compliance, and decentralized storage for secure data management.
Is the proposed system feasible for real-world implementation?
Yes, the implementation and performance evaluations show that the system is feasible, convenient, and fast, making it practical for deployment in pharmaceutical supply chains.
What are the potential benefits of this system for patients?
The system ensures the authenticity and safety of drugs, reducing the risk of counterfeit medications and improving overall patient safety.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.